Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Trastuzumab rezetecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trastuzumab rezetecan overview
Trastuzumab rezetecan (SHRA-1811) is under development for the treatment of HER2 expressing or mutated advanced malignant solid tumor, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), metastatic breast cancer, advanced non-small cell lung cancer, colorectal cancer, gastric cancer, cervical cancer, recurrent ovarian cancer and endometrial cancer and adenocarcinoma of the gastroesophageal junction. It is administered by intravenous and parenteral route. The drug candidate is an antibody drug conjugate which acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Trastuzumab rezetecan’s drug-specific PTSR and LoA scores, buy the report here.